Drugs / ROCAPULDENCEL-T
ROCAPULDENCEL-T
also known as
AGS-003 · AGS-003 MDCS · AGS-003 MDCs for drug substance AGS-003 for drug product · Arcelis
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00272649 | Jan 2006 → Feb 2012 | renal cell carcinoma | Argos Therapeutics | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01482949 | Sep 2011 → May 2018 | renal cell carcinoma | Argos Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT00678119 | Jan 2008 → May 2012 | renal cell carcinoma | Argos Therapeutics | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01582672 | Nov 2012 → Apr 2018 | renal cell carcinoma | Argos Therapeutics | Terminated | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT02170389 | Oct 2014 → Mar 2017 | renal cell carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROCAPULDENCEL-T | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545128 ↗ |
| Known as | AGS-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01482949 ↗ |
| Known as | AGS-003 MDCS | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545128 ↗ |
| Known as | AGS-003 MDCs for drug substance AGS-003 for drug product | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545128 ↗ |
| Known as | Arcelis | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545128 ↗ |
| Modality | Cell therapy | “Dendritic cell, autologous cellular immunotherapy.” NCT00272649 ↗ |